- Home
- APLE vs DNLI Comparison
APLE vs DNLI Comparison
Compare APLE & DNLI Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | APLE | DNLI |
|---|---|---|
| Founded | 2007 | 2013 |
| Country | United States | United States |
| Employees | N/A | 507 |
| Industry | Real Estate Investment Trusts | Biotechnology: Biological Products (No Diagnostic Substances) |
| Sector | Real Estate | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 3.7B | 3.4B |
| IPO Year | 2007 | 2017 |
Fundamental Metrics
Financial Performance| Metric | APLE | DNLI |
|---|---|---|
| Price | $15.55 | $21.09 |
| Analyst Decision | Buy | Strong Buy |
| Analyst Count | 8 | 14 |
| Target Price | $13.00 | ★ $34.33 |
| AVG Volume (30 Days) | ★ 1.7M | 1.1M |
| Earning Date | 05-04-2026 | 05-06-2026 |
| Dividend Yield | ★ 7.12% | N/A |
| EPS Growth | N/A | ★ N/A |
| EPS | ★ 0.40 | N/A |
| Revenue | ★ $1,238,622,000.00 | N/A |
| Revenue This Year | $2.31 | N/A |
| Revenue Next Year | $2.35 | $408.85 |
| P/E Ratio | $38.83 | ★ N/A |
| Revenue Growth | ★ 18.98 | N/A |
| 52 Week Low | $10.85 | $12.58 |
| 52 Week High | $17.28 | $27.30 |
Technical Indicators
Market Signals| Indicator | APLE | DNLI |
|---|---|---|
| Relative Strength Index (RSI) | 39.74 | 30.08 |
| Support Level | $11.54 | $17.99 |
| Resistance Level | $17.21 | $22.07 |
| Average True Range (ATR) | 0.30 | 0.74 |
| MACD | -0.09 | -0.35 |
| Stochastic Oscillator | 21.78 | 5.49 |
Price Performance
Historical ComparisonAbout APLE Apple Hospitality REIT Inc.
Apple Hospitality REIT Inc is a real estate investment trust that invests in income-producing real estate, majorly in the lodging sector, in the United States. It chiefly invests in upscale service hotels. All of the company's hotels operate under the Marriott or Hilton brands. Apple Hospitality has wholly-owned taxable REIT subsidiaries, which lease all of the company's hotels from wholly-owned qualified REIT subsidiaries. These hotels are managed under separate agreements with various hotel management companies that are unaffiliated with Apple Hospitality. The company derives its income from hotel revenue, its sole segment.
About DNLI Denali Therapeutics Inc.
Denali Therapeutics Inc is a biotechnology company that is engaged in developing and discovering therapeutics to defeat neurodegenerative diseases. The company's development programs include the LRRK2 Inhibitor Program, which develops brain penetrant small molecule LRRK2 inhibitor product candidates for Parkinson's disease. Its key products include DNL201, DNL151, ATV (Antibody Transport Vehicle), ETV (Enzyme Transport Vehicle), and others. The Company has one operating segment with the goal to discover, develop, and commercializing therapeutics.